参考文献/References:
[1]王猛,曾莉容,张弢.非ST段抬高型急性冠状动脉综合征hs-CRP、Lp(a)、CysC及ApoA与GRACE评分相关性研究[J].蚌埠医学院学报,2017,42(6):728-731. [2]徐晓晓,贾如意,王涛,等.半乳糖凝集素-3、可溶性基质溶素-2检测对心力衰竭诊断的相关性研究[J].中国循环杂志,2016,31(9):866-869. [3]徐晓晓,贾如意,王涛.半乳糖凝集素-3与心力衰竭的研究进展[J].中国循环杂志,2016,31(10):1034-1036. [4]李高楼,朱开功,杜庆钼.益气通脉汤对冠心病心绞痛病人机体Gal-3,ESM-1和Omentin-1水平的影响[J].中西医结合心脑血管病杂志,2016,14(23):2724-2727. [5]Zhong X,Qian X,Chen G,et al.The role of galectin-3 in heart failure and cardiovascular disease[J].Clin Exp Pharmacol Physiol,2019,46(3):197-203. [6]叶莎,王春亚,潘龙飞,等.半乳糖凝集素3及微量白蛋白尿与高血压患者左室肥厚的关系研究[J].中国循证心血管医学杂志,2019,11(7):814-817. [7]王宁,徐会圃.半乳糖凝集素-3与急性冠脉综合征预后相关性的研究进展[J].临床心血管病杂志,2019,35(1):88-91. [8]屈建新,邢冬梅,刘新灿.半乳糖凝集素-3在心肌纤维化相关心血管疾病中的研究进展[J].心血管病学进展,2019,40(4):605-608. [9]Jones DA,Rathod KS,Williamson A,et al.The effect of intracoronary sodium nitrite on the burden of ventricular arrhythmias following primary percutaneous coronary intervention for acute myocardial infarction[J].Int J Cardiol,2018,266(1):1-6. [10]Besler C,Lang D,Urban D,et al.Plasma and cardiac galectin-3 in patients with heart failure reflects both inflammation and fibrosis:implications for its use as a biomarker[J].Circ Heart Fail,2017,10(3):e003804. [11]Mosleh W,Chaudhari MR,Sonkawade S,et al.The therapeutic potential of blocking galectin-3 expression in acute myocardial infarction and mitigating inflammation of infarct region:a clinical outcome-based translational study[J].Biomark Insights,2018(13):1177271918771969. [12]Falcone C,Lucibello S,Mazzucchelli I,et al.Galectin-3 plasma levels and coronary artery disease:a new possible biomarker of acute coronary syndrome[J].Int J Immunopathol Pharmacol,2011,24(4):905-913. [13]Lee YJ,Koh YS,Park HE,et al.Spatial and temporal expression, and statin responsiveness of galectin-1 and galectin-3 in murine atherosclerosis[J].Korean Circ J,2013,43(4):223-230. [14]Mackinnon AC,Liu X,Hadoke PW,et al.Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice[J].Glycobiology,2013,23(6):654-663. [15]Kang Q,Li X,Yang M,et al.Galectin-3 in patients with coronary heart disease and atrial fibrillation[J].Clin Chim Acta,2018(478):166-170. [16]李玉芹,李会强.肌钙蛋白I的检测方法及研究进展[J].哈尔滨医药,2013,33(3):231-232. [17]葛均波,徐永健.内科学[M].北京:人民卫生出版社,2013:248. [18]Fuchs S,Kornowski R,Mehran R,et al.Prognostic value of cardiactroponin I levels following catheter-based coronary interventions[J].Am J Cardiol,2000(85):1077-1082.
相似文献/References:
[1]赵殿儒,祁景蕊.不同剂量瑞舒伐他汀对急性冠脉综合征患者心功能和炎症因子的影响[J].医学信息,2019,32(01):148.[doi:10.3969/j.issn.1006-1959.2019.01.046]
ZHAO Dian-ru,YAN Jing-rui.Effects of Different Doses of Rosuvastatin on Cardiac Function and Inflammatory Factors in Patients with Acute Coronary Syndrome[J].Medical Information,2019,32(01):148.[doi:10.3969/j.issn.1006-1959.2019.01.046]
[2]镡子鸣,叶怀阔,任长杰.超敏C反应蛋白及妊娠相关血浆蛋白A预测再发急性冠脉综合征的临床价值[J].医学信息,2019,32(08):173.[doi:10.3969/j.issn.1006-1959.2019.08.055]
TAN Zi-ming,YE Huai-kuo,et al.Clinical Value of High-sensitivity C-reactive Protein and Pregnancy-associated Plasma Protein A in Predicting Recurrent Acute Coronary Syndrome[J].Medical Information,2019,32(01):173.[doi:10.3969/j.issn.1006-1959.2019.08.055]
[3]梁道博,姚卜飞,夏双燕.氯吡格雷联合阿司匹林治疗急性冠脉综合征疗效与
安全性的Meta分析[J].医学信息,2019,32(11):76.[doi:10.3969/j.issn.1006-1959.2019.11.021]
LIANG Dao-bo,YAO Bu-fei,XIA Shuang-yan.Meta-analysis of the Efficacy and Safety of Clopidogrel Combined with Aspirin in the
Treatment of Acute Coronary Syndrome[J].Medical Information,2019,32(01):76.[doi:10.3969/j.issn.1006-1959.2019.11.021]
[4]张牧秋,古俊楠,刘 瑜,等.NOACS治疗房颤合并急性冠脉综合征的研究[J].医学信息,2019,32(13):28.[doi:10.3969/j.issn.1006-1959.2019.13.010]
ZHANG Mu-qiu,GU Jun-nan,LIU Yu,et al.Study of NOACS in the Treatment of Atrial Fibrillation Complicated with Acute Coronary Syndrome[J].Medical Information,2019,32(01):28.[doi:10.3969/j.issn.1006-1959.2019.13.010]
[5]王建强,刘 瑜,张牧秋,等.房颤伴ACS患者经皮冠状动脉介入术后抗栓研究[J].医学信息,2019,32(14):35.[doi:10.3969/j.issn.1006-1959.2019.14.013]
WANG Jian-qiang,LIU Yu,ZHANG Mu-qiu,et al.Study on Antithrombotic after Percutaneous Coronary Intervention in Patients with
Atrial Fibrillation and ACS[J].Medical Information,2019,32(01):35.[doi:10.3969/j.issn.1006-1959.2019.14.013]
[6]孙 洋,高 山,宋 京,等.血尿酸、同型半胱氨酸、脑钠肽、肌钙蛋白Ⅰ与急性冠脉综合征病变程度的相关性[J].医学信息,2020,33(02):105.[doi:10.3969/j.issn.1006-1959.2020.02.028]
SUN Yang,GAO Shan,SONG Jing,et al.Correlation Between Serum Uric Acid,Homocysteine,Brain Natriuretic Peptide,TroponinⅠ and the Severity of Acute Coronary Syndrome[J].Medical Information,2020,33(01):105.[doi:10.3969/j.issn.1006-1959.2020.02.028]
[7]史作霞,张文彦,李 馨,等.改良桡动脉止血器在老年ACS患者动脉穿刺后压迫止血中的效果[J].医学信息,2020,33(02):184.[doi:10.3969/j.issn.1006-1959.2020.02.060]
SHI Zuo-xia,ZHANG Wen-yan,LI Xin,et al.Evaluation of Improved Radial Arterial Hemostatic Device in Compression Hemostasis After Arterial Puncture in Elderly Patients with ACS[J].Medical Information,2020,33(01):184.[doi:10.3969/j.issn.1006-1959.2020.02.060]
[8]董 谦,陈 康,王伟佳.多重指标在急性冠脉综合症中的应用价值[J].医学信息,2021,34(05):172.[doi:10.3969/j.issn.1006-1959.2021.05.050]
DONG Qian,CHEN Kang,WANG Wei-jia.The Application Value of Multiple Indexes in Acute Coronary Syndrome[J].Medical Information,2021,34(01):172.[doi:10.3969/j.issn.1006-1959.2021.05.050]
[9]王 楠.血栓通注射液对急性冠脉综合征介入治疗后血脂、炎症因子及内皮功能的影响[J].医学信息,2021,34(09):122.[doi:10.3969/j.issn.1006-1959.2021.09.032]
WANG Nan.Effect of Xueshuantong Injection on Blood Lipid,Inflammatory Factors and Endothelial Function After Interventional Therapy for Acute Coronary Syndrome[J].Medical Information,2021,34(01):122.[doi:10.3969/j.issn.1006-1959.2021.09.032]
[10]李文军.脂蛋白相关磷脂酶A2、血清胱抑素C在急性冠脉综合征患者中表达及意义[J].医学信息,2021,34(13):70.[doi:10.3969/j.issn.1006-1959.2021.13.018]
LI Wen-jun.Expression and Significance of Lipoprotein-related Phospholipase A2 and Serum Cystatin C in Patients with Acute Coronary Syndrome[J].Medical Information,2021,34(01):70.[doi:10.3969/j.issn.1006-1959.2021.13.018]